Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
announced wind-down in 2023
|
| gptkbp:CEO |
gptkb:David_Cory
|
| gptkbp:clinicalTrialPhase |
conducts clinical trials for rare disease therapies
|
| gptkbp:developedBy |
therapies for hepatitis delta virus (HDV)
therapies for lymphedema therapies for progeria |
| gptkbp:focusesOn |
rare diseases
orphan diseases |
| gptkbp:founded |
2008
|
| gptkbp:headquartersLocation |
gptkb:Palo_Alto,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eiger BioPharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:numberOfEmployees |
approximately 50 (as of 2022)
|
| gptkbp:product |
gptkb:Zokinvy
Lonafarnib Peginterferon Lambda |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
EIGR
|
| gptkbp:website |
https://www.eigerbio.com/
|
| gptkbp:bfsParent |
gptkb:lonafarnib
|
| gptkbp:bfsLayer |
7
|